| Literature DB >> 23577220 |
A C Fortes1, A A C Almeida, G A L Oliveira, P S Santos, W De Lucca Junior, F J B Mendonça Junior, R M Freitas, J L Soares-Sobrinho, M F R Soares.
Abstract
2-[(2,6-Dichlorobenzylidene)amino]-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carbonitrile, 5TIO1, is a new 2-aminothiophene derivative with promising pharmacological activities. The aim of this study was to evaluate its antioxidant activity in different areas of mice central nervous system. Male Swiss adult mice were intraperitoneally treated with Tween 80 dissolved in 0.9% saline (control group) and 5TIO1 (0.1, 1, and 10 mg kg(-1)). Brain homogenates-hippocampus, striatum, frontal cortex, and cerebellum-were obtained after 24 h of observation. Superoxide dismutase and catalase activities, lipid peroxidation and nitrite content were measured using spectrophotometrical methods. To clarify the 5TIO1's mechanism on oxidative stress, western blot analysis of superoxide dismutase and catalase was also performed. 5TIO1 decreased lipid peroxidation and nitrite content in all brain areas and increased the antioxidant enzymatic activities, specially, in cerebellum. The data of Western blot analysis did not demonstrate evidence of the upregulation of these enzymes after the administration of this compound. Our findings strongly support that 5TIO1 can protect the brain against neuronal damages regularly observed during neuropathologies.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23577220 PMCID: PMC3612446 DOI: 10.1155/2013/194192
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1Chemical structure of 5TIO1.
Determination of the lipid peroxidation levels in hippocampus, striatum, frontal cortex, and cerebellum of mice treated with 5TIO1 at doses 0.1, 1, and 10 mg kg−1.
| Groups | TBARS (mmol min−1
| |||
|---|---|---|---|---|
| Hippocampus | Striatum | Frontal cortex | Cerebellum | |
| Vehicle | 1.36 ± 0.14 | 1.34 ± 0.06 | 1.54 ± 0.04 | 1.43 ± 0.06 |
| 5TIO1 0.1 | 0.13 ± 0.03a | 0.13 ± 0.01a | 0.12 ± 0.02a | 0.13 ± 0.03a |
| 5TIO1 1 | 0.16 ± 0.01a | 0.16 ± 0.01a | 0.15 ± 0.01a | 0.18 ± 0.03a,b |
| 5TIO1 10 | 0.15 ± 0.01a | 0.15 ± 0.02a | 0.15 ± 0.01a | 0.17 ± 0.03a,b |
Male mice (25–30 g, 2 month-old) were intraperitoneally treated with doses of 5TIO1 (0.1, 1, and 10 mg kg−1, n = 7, 5TIO1 groups) and the control animals with 0.05% Tween 80 dissolved in 0.9% saline (n = 7, Vehicle). Results are expressed as means ± SD for the number of animals shown inside in parenthesis. Differences in experimental groups were determined by two-tailed Analysis of Variance (ANOVA). a P < 0.05 compared to the control group (ANOVA and t-Student-Neuman-Keuls as post hoc test); b P < 0.05 compared to the 5TIO1 0.1 group (ANOVA and t-Student-Neuman-Keuls as post hoc test).
Nitrite content in hippocampus, striatum, frontal cortex, and cerebellum of mice treated with 5TIO1 at doses 0.1, 1, and 10 mg kg−1.
| Groups | Nitrite ( | |||
|---|---|---|---|---|
| Hippocampus | Striatum | Frontal cortex | Cerebellum | |
| Vehicle | 95.86 ± 7.67 | 94.71 ± 3.35 | 76.57 ± 1.72 | 82.43 ± 1.99 |
| 5TIO1 0.1 | 5.11 ± 1.16a | 6.00 ± 1.82a | 6.49 ± 1.97a | 6.93 ± 2.25a |
| 5TIO1 1 | 6.36 ± 2.73a | 4.98 ± 1.51a | 6.19 ± 3.24a | 4.81 ± 1.43a |
| 5TIO1 10 | 7.14 ± 2.62a | 9.04 ± 6.54a | 8.50 ± 3.33a | 9.04 ± 4.76a |
Male mice (25–30 g, 2 month-old) were intraperitoneally treated with doses of 5TIO1 (0.1, 1, and 10 mg kg−1, n = 7, 5TIO1 groups) and the control animals with 0.05% Tween 80 dissolved in 0.9% saline (n = 7, Vehicle). Results are expressed as means ± SD for the number of animals shown inside in parenthesis. Differences in experimental groups were determined by two-tailed Analysis of Variance (ANOVA). a P < 0.05 compared to the control group (ANOVA and t-Student-Neuman-Keuls as post hoc test).
Catalase activity in hippocampus, striatum, frontal cortex, and cerebellum of mice treated with 5TIO1 at doses 0.1, 1, and 10 mg kg−1.
| Groups | Catalase (U | |||
|---|---|---|---|---|
| Hippocampus | Striatum | Frontal cortex | Cerebellum | |
| Vehicle | 14.22 ± 1.54 | 19.35 ± 0.46 | 22.51 ± 0.37 | 24.61 ± 0.42 |
| 5TIO1 0.1 | 33.62 ± 2.52a | 20.39 ± 2.79 | 15.41 ± 2.45a | 33.62 ± 2.52a |
| 5TIO1 1 | 35.94 ± 2.57a | 26.36 ± 4.93 | 29.91 ± 5.54a,b | 35.94 ± 2.57a |
| 5TIO1 10 | 34.98 ± 3.24a | 30.52 ± 7.12a,b | 34.03 ± 3.32a,b,c | 34.98 ± 3.24a |
Male mice (25–30 g, 2 month-old) were intraperitoneally treated with doses of 5TIO1 (0.1, 1, and 10 mg kg−1, n = 7, 5TIO1 groups) and the control animals with 0.05% Tween 80 dissolved in 0.9% saline (n = 7, Vehicle). Results are expressed as means ± SD for the number of animals shown inside in parenthesis. Differences in experimental groups were determined by two-tailed Analysis of Variance (ANOVA). a P < 0.05 compared to the control group (ANOVA and t-Student-Neuman-Keuls as post hoc test); b P < 0.05 compared to the 5TIO1 0.1 group (ANOVA and t-Student-Neuman-Keuls as post hoc test); c P < 0.05 compared to the 5TIO1 1 group (ANOVA and t-Student-Neuman-Keuls as post hoc test).
Superoxide dismutase activity in hippocampus, striatum, frontal cortex, and cerebellum of mice treated with 5TIO1 at doses 0.1, 1, and 10 mg kg−1.
| Groups | Superoxide dismutase (U | |||
|---|---|---|---|---|
| Hippocampus | Striatum | Frontal cortex | Cerebellum | |
| Vehicle | 2.24 ± 0.41 | 2.64 ± 0.49 | 2.20 ± 0.07 | 3.23 ± 0.35 |
| 5TIO1 0.1 | 3.56 ± 1.63a | 2.86 ± 0.31a | 2.52 ± 0.23a | 3.95 ± 1.84a |
| 5TIO1 1 | 3.14 ± 0.42a | 2.54 ± 0.89 | 2.39 ± 0.44a | 2.81 ± 1.96 |
| 5TIO1 10 | 2.16 ± 0.79 | 2.42 ± 0.38 | 2.17 ± 0.34 | 2.70 ± 1.34 |
Male mice (25–30 g, 2 month-old) were intraperitoneally treated with doses of 5TIO1 (0.1, 1, and 10 mg kg−1, n = 7, 5TIO1 groups) and the control animals with 0.05% Tween 80 dissolved in 0.9% saline (n = 7, Vehicle). Results are expressed as means ± SD for the number of animals shown inside in parenthesis. Differences in experimental groups were determined by two-tailed Analysis of Variance (ANOVA). a P < 0.05 compared to the control group (ANOVA and t-Student-Neuman-Keuls as post hoc test).
Figure 2Superoxide dismutase and catalase proteins in hippocampus, striatum, frontal cortex, and cerebellum of mice treated with vehicle and 5TIO1. Male mice (25–30 g, 2 month-old) were intraperitoneally treated with 0.25 mL of 0.05% Tween 80 dissolved in 0.9% saline (vehicle) (n = 7, control group), and 5TIO1 groups with 2-[(2,6-dichlorobenzylidene)amino]-5,6-dihydro-4H-cyclopenta [b]thiophene-3-carbonitrile emulsified in vehicle (0.1, 1, and 10 mg/kg, n = 7, 5TIO1 groups). Animals were observed for 24 h and then killed. The protein amount per lane was 10 Ag. Legends: (I) control group; (II) 5TIO1 0.1 mg/kg group; (III) 5TIO1 1 mg/kg group; (IV) 5TIO1 10 mg/kg group. Data are expressed as means ± SD, converted to percentage of control (set at 100%) n = 4 experiments; Statistical analysis was by one-way ANOVA and t-Student-Neuman-Keuls test as post hoc test. There were no significant differences in protein expression of catalase after treatments, although there was a significant difference (P > 0.05).